Is a powerhouse Merck team preparing to leap past Roche — and leave Gilead and Bristol Myers behind — in the race to TIGIT domination?
Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
